N- and O-glycans • Defined terminal epitopes • Presentation-aware research panels
BOC Sciences provides mammalian glycan synthesis support for antibody and glycoprotein glycoform research, receptor recognition, cell adhesion, and disease-associated glycosylation studies. Targets include high-mannose, hybrid, and complex N-glycans, mucin-type O-glycans, and defined sialylated or fucosylated structures. Each project specifies branch architecture, residue linkages, core modifications, and the presentation required for the intended experiment.
Mammalian glycan project families. Exact residue structures, branch positions, terminal linkages, and molecular presentation are specified separately; the cards are not molecular structures.Project specification
Custom synthesis scope
A glycan composition can correspond to multiple branch or linkage isomers. We use a complete target structure to connect the chosen glycan family with the specific biological comparison. Human targets and other mammalian structures are distinguished where residue identity or modification differs.
Discuss high-mannose structures such as specified Man5-Man9 targets, hybrid structures with different arm compositions, and complex structures with defined antennae. Mannose count or antenna number alone may not identify a unique glycan. Branch placement, terminal sugars, bisecting GlcNAc, and core fucosylation are included where relevant.
Plan O-GalNAc structures with the required core, extension, terminal epitope, and attachment format. A free oligosaccharide, an alpha-GalNAc derivative, and an O-glycopeptide are different materials. If a peptide context is needed, specify the Ser/Thr site and sequence rather than assuming that a released O-glycan reproduces the native attachment.
Prepare targets differing in sialic-acid linkage, fucose placement, or terminal extension. Neu5Ac and Neu5Gc are specified separately; Neu5Gc is relevant to some nonhuman mammalian contexts and is not a routine human glycan residue. Core alpha1,6 fucose and antennary fucose describe distinct structural features.
Discuss reducing-end handles, labels, and other derivatives for immobilization or conjugation. The linker, attachment chemistry, and delivered glycan form are identified in the specification. A free glycan or neoglycoconjugate does not recreate every effect of protein conformation, site occupancy, density, or neighboring glycans.

Target-specific route assessment
Chemical, enzymatic, and combined routes offer different access to mammalian glycan structures. Target definition, enzyme substrate scope, branch selectivity, and the required reducing end guide route selection.
The synthesis map identifies the N-glycan core or O-glycan core before extension. Antenna composition is recorded by arm, including asymmetric structures and partial terminal modification. A composition code or total sialic-acid count is supplemented with a drawing when positional identity matters.
Transferase-based extension can access selected termini when suitable acceptors are available. Chemical assembly may be needed for unusual cores, modifications, or attachment formats. Published enzyme acceptance for one substrate does not establish activity on every branched or derivatized analog.
Sialylated and other labile structures require compatible reaction, purification, and storage conditions. The final label or linker may change separation behavior. Characterization is performed on the delivered material, with free and derivatized forms distinguished in the data record.
Material and project decisions
Useful comparisons preserve selected features while changing the structural variable under study. The following decisions should be made before synthesis rather than inferred from a family name.
| Research variable | Structural definition | Useful comparison |
|---|---|---|
| Mannose trimming | Exact high-mannose branch structure at each residue count | Defined Man5-Man9 members or selected branch isomers |
| Hybrid versus complex architecture | Composition and extension of each arm | Structures with selected terminal features held constant |
| N-glycan core modification | Bisecting GlcNAc, alpha1,6 core fucose, and all other residues | A matched pair with one declared core change |
| Terminal sialylation | Neu5Ac/Neu5Gc identity, linkage, and modified arm | Specified alpha2,3/alpha2,6 or occupancy series |
| Mucin-type O-glycan extension | Core sequence, terminal motif, and attachment format | Core or extension variants with comparable presentation |
| Protein-context effects | Protein, glycosylation site, occupancy, and neighboring structures | Separate glycan and defined glycoconjugate experiments |
Our Glycan Synthesis Services provide a broader entry point, while Glycan Conjugation Services support separately scoped attachment projects. Individual glycoform studies require agreement on both the glycan structure and its molecular context.
Structure-to-data consistency
Analytical requirements depend on whether the study needs family identity, an isolated isomer, or a fully assigned derivative. No single composition measurement answers all three questions.
Composition
Mass analysis supports the proposed glycan composition and final derivative. It does not independently locate a fucose, identify a modified arm, or distinguish every isomer. Salt forms, reducing-end chemistry, and labels are considered during interpretation.
Connectivity
Suitable NMR, fragmentation, and selective enzymatic evidence can contribute to the assignment. The agreed package states which arms, terminal linkages, and core modifications need confirmation. A biosynthetic label alone is not sufficient evidence for a unique asymmetric structure.
Separation
Chromatography is selected to assess relevant precursors, partially extended species, and plausible isomers. Peak area and structural confidence are reported separately. Where a reference or resolving method is unavailable, that limitation remains explicit in the analytical record.
Presentation
For functionalized glycans, confirm the linker or label and the intended attachment state. Conjugation metrics and protein-site occupancy belong to a separately agreed glycoconjugate package. Free-glycan purity does not establish a homogeneous glycoprotein glycoform.
Research applications
Defined synthetic structures help separate glycan variables that are difficult to resolve in heterogeneous biological samples. Results remain dependent on presentation and the experimental system.
Use structurally defined glycans as references or as inputs to a separately designed remodeling or conjugation project. Changes in a free glycan cannot by themselves predict antibody effector function or protein behavior. Protein identity, site occupancy, and attached glycoform distribution require their own evidence.
Compare branch architecture, core modifications, or terminal epitopes using a controlled panel. Ligand density, immobilization orientation, and multivalent display can alter apparent recognition. Matched derivatives help distinguish the selected structural variable from avoidable presentation differences.
Investigate specified epitopes in adhesion or disease-related research models without treating a glycan motif as disease-specific. Sialylation and fucosylation occur in many biological contexts. Suitable controls and the chosen cell or receptor model determine what an observed response can support.
A defined synthesis project
The project starts with the glycan variable and the form in which it will be studied, then aligns assembly, separation, and structural evidence.
Project brief
Send the complete glycan drawings, species context, arm-specific modifications, reducing end, intended assay format, desired amount, and any paired glycoform references.

Confirm N- or O-glycan type, all linkages, core features, and terminal residue identities. Expand ambiguous composition codes into drawings.

Choose branch, core, or terminal variants and record the features held constant. Distinguish glycan-only comparisons from protein-context experiments.

Review chemical or enzyme-mediated access alongside label, linker, or glycopeptide requirements. Scope attached glycoprotein work separately where needed.

Isolate the agreed structures and collect composition, connectivity, and separation evidence appropriate to the requested resolution.

Provide individual identities, analytical records, and handling information. Keep optional recognition measurements linked to their actual assay conditions.
Project advantages
BOC Sciences coordinates family-level synthesis planning with the details that determine whether a mammalian glycan panel can answer the intended research question.
The project goes beyond total residue counts to identify branch architecture and positions of terminal or core modifications.
Free glycans, labeled derivatives, glycopeptides, and protein-attached glycoforms are distinguished before defining deliverables.
Reference structures and analytical requirements are selected around the variable being investigated, with sensitive terminal residues considered during processing.
One connected glycan platform
Related insights
Explore supporting information on synthesis, characterization, and material selection for your project.
Frequently asked questions
Answers to common questions about the requested structures, characterization, and project scope.
Targets include high-mannose, hybrid, and complex N-glycans, mucin-type O-glycans, and specified sialylated or fucosylated structures. Feasibility depends on the exact drawing, final derivative, quantity, and required structural resolution.
No. Branch, linkage, and modification-position isomers can share a composition. Supply a complete drawing and identify each arm when positional structure matters.
Yes. Specify Neu5Ac or another requested sialic acid, alpha2,3 or alpha2,6 linkage where relevant, and the modified arm. Human and nonhuman mammalian contexts should be identified explicitly.
Free glycans are useful structural materials, but they do not reproduce protein conformation, glycosylation-site occupancy, or the distribution of attached glycans. A defined glycoprotein project requires a separate specification and characterization plan.
Provide the core and extensions, terminal epitopes, GalNAc attachment format, and whether the deliverable is a free glycan, derivative, or glycopeptide. For a glycopeptide, specify the peptide sequence and glycosylation site.
Define the research material your project needs
Share your N- or O-glycan targets with BOC Sciences, including each arm, core modification, terminal epitope, and intended presentation. Add the research comparison, desired amounts, and analytical requirements. We can assess a synthesis plan for defined materials that support your glycoform, recognition, or cell-adhesion study.
Contact BOC Sciences to discuss target-specific feasibility, specifications, and the required analytical package. Materials are intended for research use.